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Abstract
The most common cause of death of cancer sufferers is through the occurrence of metastases. The
metastatic behaviour of tumour cells is regulated by extracellular growth factors such as
hepatocyte growth factor (HGF), a ligand for the c-Met receptor tyrosine kinase, and aberrant
expression/activation of the c-Met receptor is closely associated with metastatic progression. Nk4
(also known as Interleukin (IL)32b) is a competitive antagonist of the HGF c-Met system and inhibits
c-Met signalling and tumour metastasis. Nk4 has an additional anti-angiogenic activity independent
of its HGF-antagonist function. Angiogenesis-inhibitory as well as cancer-specific apoptosis inducing
effects make the Nk4 sequence an attractive candidate for gene therapy of cancer. This study
investigates the inhibition of tumour metasasis by gene therapy mediated production of Nk4 by the
primary tumour. Optimal delivery of anti-cancer genes is vital in order to achieve the highest
therapeutic responses. Non-viral plasmid delivery methods have the advantage of safety and ease
of production, providing immediate transgene expression, albeit short-lived in most tumours.
Sustained presence of anti-angiogenic molecules is preferable with anti-angiogenic therapies, and
the long-term expression mediated by Adeno-associated Virus (AAV) might represent a more
appropriate delivery in this respect. However, the incubation time required by AAV vectors to
reach appropriate gene expression levels hampers efficacy in many fast-growing murine tumour
models. Here, we describe murine trials assessing the effects of Nk4 on the spontaneously
metastatic Lewis Lung Carcinoma (LLC) model when delivered to primary tumour via plasmid
lipofection or AAV2 vector. Intratumoural AAV-Nk4 administration produced the highest
therapeutic response with significant reduction in both primary tumour growth and incidence of
lung metastases. Plasmid-mediated therapy also significantly reduced metastatic growth, but with
moderate reduction in primary subcutaneous tumour growth. Overall, this study demonstrates the
potential for Nk4 gene therapy of metastatic tumours, when delivered by AAV or non-viral
methods.
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Findings
HGF is a heterodimeric molecule and functions include
mitogenic, motogenic, morphogenic and anti-apoptotic
activities [1,2]. HGF plays roles in organizing tissues dur-
ing development and regeneration, but in cancer stimu-
lates malignant cell invasive behaviour [3-5]. Nk4 consists
of the N-terminus of HGF (447 amino acids of α-chain),
which contains an N-terminal hairpin and four kringle
domains (β-chain removed) [6]. This molecule inhibits
cell proliferation and induces apoptosis by the first kringle
domain [7] and promotes anti-angiogenic activities
through the competitive inhibition of binding of ang-
iogenic growth factors to endothelial cells by its N-termi-
nus [8].
This study describes murine trials assessing the effects of
Nk4 gene therapy on the spontaneously metastatic
murine LLC model when delivered to the primary tumour
via plasmid lipofection or AAV2 vector. DNA constructs
are shown in figure 1. The Nk4 expressing plasmid pSe-
lectBlasti-2BhIL32b and the equivalent backbone pSelect-
Blasti-MCS were purchased from Invivogen (Cayla SAS,
Toulouse, France). LLC cell line was purchased from
ATCC and maintained according to ATCC recommenda-
tions. In order to administer gene as early as possible in
tumour growth (smallest injectable tumour size), plasmid
DNA (prepared using Endotoxin free Plasmid MegaPrep
Kit (Qiagen, West Sussex, UK)) was delivered to tumours
using Lipofectamine2000 (Invitrogen Corp., Paisley, Scot-
land) at day 7-post tumour induction. The transfectability
of LLC with lipofectamine 2000 was demonstrated in vitro
with pEGFP-F delivery as assessed by fluorescent micros-
copy (data not shown), and in vivo (figure 2b). Nk4
expression in pSelectBlasti-2BhIL32b transfected LLC cells
was demonstrated in vitro by RT-PCR (figure 2a). All in
vivo experiments were approved by the ethics committee
of University College Cork. Subcutaneous (s.c.) LLC
tumours were induced in 6–8 week old female C57 mice
obtained from Harlan Laboratories (Oxfordshire, Eng-
land) using 2 × 105 cells, suspended in 200 μl serum free
Dulbecco Modified Eagle Medium, DMEM, (GIBCO, Inv-
itrogen Corp., Paisley, Scotland) injected subcutaneously
into the flank. When the tumours reached an average vol-
ume of 0.1 cm3, they were intratumourally (i.t.) adminis-
tered 75 μl plasmid/lipofectamine2000 mix containing
25 μg DNA corresponding to Nk4-coding or Backbone
(BB) plasmid, or received no treatment (n = 9). The firefly
luciferase coding plasmid pCMVluc (Plasmid Factory,
Germany) was also administered to a group to validate
transfection (n = 3) and IVIS imaged at 24 h. 1.64 × 10-8
p/sec/cm2/sr/plasmid copy was observed confirming the
transfectability of LLC tumours by this method (figure
2b).
Tumour growth was monitored by alternate day measure-
ments in two dimensions using a Verniers callipers.
Tumour volume was calculated according to the formula
V = (ab2)∏/6. At each time point, a two-sampled t-test was
used to compare mean tumour volume within each treat-
ment group. Microsoft Excel (Microsoft) was used to man-
age and analyze data. Statistical significance was defined
at the standard 5% level. Figure 2c shows tumour growth
Vector Constructs Figure 1
Vector Constructs. pSelectBlasti-MCS and pSelectBlasti-2BhIL32b were purchased from Invivogen (Cayla SAS, Toulouse, 
France). Coding sequences (IL32 and Bsr = Blasticidin resistance gene) are indicated in dark outline. The functionality of the 
human IL32b sequence in mice has previously been published [16]. The CMV and hEF1/HTLV composite promoters are indi-
cated in grey. For AAV vector constructs, the IL32 (Nk4) expression cassette including the blasticidin resistance gene was PCR 
amplified using primers designed with a XhoI and HindIII restriction site overhang, (forward-hindIII: 
5'AGCAGCAGCTTCCCTGCTTGCTCAACTCTAC3', reverse-xhoI: 
5'AGCAGCCTCGAGCAGGCGTTACATAACTTACGG3'and cloned into pAAV-MCS. Clone sequences were validated by 
sequencing (MWG Biotech).
pSelect-blasti-mcs hEF1/HTLV SV40 pAn
ITR ITR
MCS
BGlo pAn Bsr EM7 CMV 
HindIII XhoI
ori
pSelect2B-hIL32b hEF1/HTLV SV40 pAn BGlo pAn Bsr EM7 CMV 
HindIII XhoI
ori hIL32b
pAAV2-BB
pAAV2-Nk4
SV40 pAn BGlo pAn Bsr EM7 CMV 
HindIII XhoI
CMV  BGlo intron hGH pAn
ITR ITR
SV40 pAn BGlo pAn Bsr EM7 CMV 
HindIII
XhoI
hIL32b CMV  BGlo intron hGH pAn
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curves for the various groups (n = 6). While the Nk4
treated group showed a reduction in tumour size when
compared with the control groups, the difference was not
statistically significant. Three sample mice (external to
measurement groups) from each group were culled at day
21 for analysis of lung metastases. Immediately post cull-
ing by cervical dislocation, mouse lungs were excised and
fixed in Bouin's solution (Sigma, Dublin, Ireland) over-
night to visualise metastatic foci macroscopically (figure
2d). No statistical significance was observed between
groups in average numbers of macroscopic lung metas-
tases. As some untreated mice had fewer but larger metas-
tases than the treated group, the metastases volume was
determined by measurement of the volume of the nodules
(using a Verniers callipers and calculated as before). The
Nk4 treated group had significantly reduced average met-
astatic burden when compared with the untreated control
group in this context (p = 0.03) (figure 2e).
While both plasmid and adenoviral vectors have been uti-
lised for Nk4 gene therapy of cancer [9-11], the short lived
expression in tumours associated with these vectors may
Plasmid mediated Nk4 gene therapy of LLC tumours Figure 2
Plasmid mediated Nk4 gene therapy of LLC tumours. (a) Nk4 plasmid expression in vitro LLC cells were transfected 
with pSelectBlasti-2BhIL32b by lipofection in vitro. cDNA was prepared from total RNA extracted at 24 h, and subjected to 
PCR with primers specific for a 300 bp Nk4 sequence (5'CCTCTCTGATGACATGAAGAAG3', 
5'TGTCACAAAAGCTCTCCCC3'). Lane 1 = RNA from LLC transfected with pSelectBlasti-2BhIL32b, lane 2 = pSelectBlasti-
2BhIL32b DNA, lane 3 = RNA from untransfected LLC cells, lane 4 = H2O template control. (b) Transfection of LLC 
tumours in vivo In vivo luciferase activity from pCMV Luc transfected tumours was analysed. 100 μl 6 mg/ml luciferin (Biosynth, 
Switzerland) was injected i.p. and i.t. Mice were anaesthetised by i.p. administration of 100 μg xylazine and 1 mg ketamine. Ten 
minutes post-luciferin injection, mice were imaged for 1 min using an intensified CCD camera (IVIS Imaging System, Xenogen). 
1.64 × 10-8 p/sec/cm2/sr/plasmid copy was observed. (c) Tumour growth curve of LLC treated tumours Time points of 
treatment and lung excision are indicated. Nk4 treated group showed reduction in tumour size compared with the other con-
trol groups, indicating Nk4 effect on tumour growth although not statistically significant. (n = 6) (d) Macroscopic LLC meta-
static lung nodules Nodules appear as dark red spots on freshly excised lung, or light yellow colour on lungs fixed in Bouin's 
solution O/N. Cross sections show the morphological appearance of tumours on the inside of the lungs. Lungs were harvested 
from mice at day 21 post tumour induction. (e) Average volume of lung metastases The Nk4 group exhibited a significant 
reduction in metastatic burden compared with control groups (n = 3). Significant difference was observed in the volume of 
metastases between the Nk4 treated group compared with both the untreated group (p = 0.004), and the backbone group (p 
= 0.029). No statistical difference was observed between backbone and untreated groups (p = 0.587).
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reduce therapeutic efficacy. AAV shows promise for anti-
angiogenic gene therapy as it has been demonstrated that
this vector can maintain gene expression for over 1 year
[12-14] and elicits no cell-mediated immune response. To
assess if prolonged and increased levels of expression at
later time points would improve therapeutic responses,
AAV2 mediated delivery of the Nk4 cassette was exam-
ined. The recombinant plasmids pAAV-Nk4 and pAAV-
BB, were constructed as described in figure 1. AAVCMV-
Luc was generated by cloning of the Nco1, Xba1 fragment
of pGL3 (Promega) containing the firefly luciferase gene,
by blunt end ligation in the EcoRI, Xba1 region down-
stream of the CMV promoter of AAV-MCS cloning vector
(Stratagene). AAV2 vector particles were prepared using
the Stratagene AAV Helper Free System (Techno-Path,
Limerick, Ireland), and concentrated using the Virakit sys-
tem (Virapur, California, USA). Cells transduced with
AAV-LacZ (Stratagene) particles were assessed for β-Galac-
tosidase activity microscopically to determine the titre of
the particle stocks, in parallel with AAV-Nk4 and AAV-BB.
Nk4 expression was validated by reverse transcription
PCR (RT-PCR) (Omniscript RT kit (Qiagen)) using prim-
ers forward CCTCTCTGATGACATGAAGAAG and reverse
TGTCACAAAAGCTCTCCCC.
Subcutaneous LLC tumours were induced in C57 mice
and at an average volume of 0.1 cm3, i.t. administered 107
particles/40 μl AAV-Nk4, AAV-BB or PBS (n = 9). Tumour
volumes were measured at regular intervals and 3 mice of
each group were culled at 2 time points during the trial for
analysis of lung metastases. The effects of AAV particles on
tumour growth are detailed in figure 3. The s.c. tumour
growth curve illustrates a marked decrease in growth in
the AAV-Nk4 treated group in comparison with the
untreated group and the AAV-BB control group. Unex-
pectedly, the backbone DNA containing AAV appeared to
increase s.c. tumour growth, although not significantly.
Significant difference was observed on days 10, 12, 21, 24
and 26 between the AAV-Nk4 and AAV-BB group (p <
0.05). Significant difference between the Nk4 treated and
untreated group was approached towards the latter stages
of the experiment but the trial had to be discontinued due
to the tumour burden in the control groups in order to
comply with ethical guidelines.
Pulmonary metastatic burden was assessed by visual
counts at day 21 and 26. Mice in the control groups (BB
and Untreated) showed more metastatic burden on both
time points than the AAV-Nk4 treated group, and the BB
group displayed increased (but statistically insignificant)
metastatic burden over the untreated group (data not
shown). Combined Day 26 and Day 21 measurements are
shown in figures 3d &3e. Statistically significant differ-
ences in average numbers of lung metastases were seen
between the Nk4 and BB group (p = 0.015) (figure 3d).
When volumes of metastatic nodules were measured, the
overall metastatic burden was significantly lower in the
AAV-Nk4 treated group compared with both control
groups; BB control group (p = 0.012), untreated group (p
= 0.021) (figure 3e). It is unknown why AAV-BB increased
tumour growth and metastases, and this was not observed
in the plasmid experiments, suggesting that it is not as a
result of DNA sequence, at least at the level of plasmid-
mediated expression. Nevertheless, it cannot be ruled out
that elements of the AAV vector were counteracting the
therapeutic efficacy of Nk4.
It has previously been reported that by day 6 post tumour
inoculation, 100% LLC mice have already developed met-
astatic disease [15]. In our trials, the earliest possible day
of AAV injection into the tumours (minimum injectable
size 0.1 cm3) was day 7. Others have addressed the limita-
tion associated with AAV delayed expression by the use of
self-complementary AAV [16]. It is plausible that
increased therapeutic efficacy might be observed by
achieving gene expression earlier in tumour growth and
spread. The AAV2/2 serotype used in our studies has only
a 30% reported efficiency of transducing LLC in vitro [17].
We observed an even lower efficiency (data not shown).
Administration of a higher dose of AAV particles may
increase effects on tumour growth and metastasis. This
notwithstanding, AAV achieved dramatically higher
expression levels per gene copy than plasmid (10-3 p/sec/
cm2/sr/AAVparticle vs 10-8 p/sec/cm2/sr/plasmid copy).
The significant differences in effects on tumours between
the Nk4 containing and Nk4-free controls, coupled with
demonstration of in vivo reporter gene expression in LLC
tumours, as well as in vitro Nk4 expression data, indicate
that Nk4 sequences were responsible for the observed
effects on tumour growth.
Duration of gene expression is an important factor to be
addressed in such gene therapies. It has previously been
reported that slow release of NK4 plasmid DNA from cat-
ionised gelatin increases efficacy of Nk4 plasmid therapy
[18]. While we did not investigate whether the superior
responses observed with AAV over plasmid were as a result
of increased duration or level of AAV expression, it is pos-
sible that a combination of the two systems described here
may result in both immediate and long-term therapeutic
expression enabled by plasmid initially, then to be super-
seded upon AAV activation.
The nature of our LLC model meant that it was not possi-
ble to generate survival curves based on death due to met-
astatic disease, as trials had to be stopped at or prior to 26
days post tumour inoculation due to primary tumour size.
Plasmid experiments were ceased at day 21, due to early
ulceration of tumours at subsequent times in plasmid
administered groups, possibly related to toxicity of lipo-Genetic Vaccines and Therapy 2009, 7:5 http://www.gvt-journal.com/content/7/1/5
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fectamine. No such ulceration was observed in AAV
administered tumours up to day 26. A tumour model per-
mitting longer-term study of this therapy would yield fur-
ther information. Given the distance from clinical reality
of fast-growing murine tumour models, anti-metastatic
therapy as described here may yet prove a powerful thera-
peutic strategy in humans, especially if applied earlier in
tumour progression.
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Subcutaneous and metastatic LLC growth following AAV-mediated Nk4 Gene Therapy Figure 3
Subcutaneous and metastatic LLC growth following AAV-mediated Nk4 Gene Therapy. (a) AAVNk4 expression 
in vitro LLC cells were transduced with AAVNk4 particles in vitro. cDNA was prepared from total RNA extracted at 48 h, and 
subjected to Nk4 specific RT-PCR as before. Lane 1 = RNA from LLC transduced with AAVNk4 particles, lane 2 = RNA from 
untransduced LLC cells, lane 3 = H2O template control. (b) AAV transduction of LLC tumours In vivo luminescence in LLC 
tumour following i.t. adminstration of AAV-CMV Luc particles. Image from IVIS Imaging System showing luciferase expression 
on day 9 post i.t. injection of AAV-Luc particles (2.91 × 10-3 p/sec/cm2/sr/particle). (c) In vivo treatment of growing LLC 
tumours with AAV-Nk4 Established LLC tumours were i.t. administered AAV-Nk4 or AAV-BB (control) or no particles (PBS) 
and growth monitored (n = 6). Tumour growth in the AAV-Nk4 group was significantly reduced (*p < 0.05) when compared 
with the AAV-BB injected control group, and while the untreated group growth was also higher than the Nk4 group, it proved 
to be statistically insignificant. (d) Number of lung metastases following AAV-Nk4 therapy Visual analysis and comparison 
of surface metastatic nodules at days 21 and 26 showed that the Nk4 treated group had fewer nodules compared with the BB 
and untreated control group. A statistically significant difference could be seen between the combined day 21 and day 26 data 
from the Nk4 treated group and the BB control group (p = 0.015) (n = 3/group/timepoint). (e) Volume of lung metastases 
following AAV-Nk4 therapy Metastatic nodules were measured at days 21 and 26 and the average volume calculated. Both 
control groups had a larger metastatic burden than the Nk4 treated group with a significant difference between the Nk4 and 
untreated group (p = 0.021) and the BB group (p = 0.012).
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